Preeclampsia Clinical Trial
Official title:
The Predictive Use of Spot Urine Protein/Creatinine Ratios and Decreased Sample Collection Time in the Diagnosis of Preeclampsia
The investigators intend to perform a large prospective study looking at the predictability of the random urine protein-to-creatinine ratio compared to the gold standard 24-hour urine protein collection. Furthermore, the investigators plan to investigate whether analysis of proteinuria at shorter time intervals (4 and 8 hours) within the overall 24-hour collection period is predictive of the 24-hour sample. Lastly, the investigators plan to determine whether a combination of the random test with a shorter collection interval is comparable to the 24-hour collection.
Preeclampsia affects approximately 5-8% of pregnancies in the United States with approximately 10% occurring before 34 weeks gestation. The diagnosis of preeclampsia is determined by the presence of hypertension with proteinuria after 20 weeks gestation. The gold standard for measuring proteinuria is a 24-h urine collection for total protein. In the non-pregnant patient, a random urinary protein-to-creatinine ratio has been shown to be a reliable indicator of significant proteinuria. The reliability of this test remains unclear in the pregnant population. Because there are relatively few studies in the pregnant population and many of these studies were poorly designed, limited by sample size, or confounded by other variables, further research in this area is still necessary. The purpose of this study is to determine if there are alternative diagnostic tools for the quantification of total protein excretion in 24-hours to aid in the diagnosis of preeclampsia that can be performed more quickly and efficiently than the gold standard 24-hour urine collection. We intend to perform a large prospective study looking at the predictability of the random urine protein-to-creatinine ratio compared to the gold standard 24-h urine protein collection. Furthermore, we plan to investigate whether analysis of proteinuria at shorter time intervals (4 and 8 hours) within the overall 24-h collection period is predictive of the 24-h sample. Lastly, we plan to determine whether a combination of the random test with a shorter collection interval is comparable to the 24-h collection. The goal would be to make the diagnosis of preeclampsia in a more timely fashion to aid in the prevention of maternal and neonatal morbidity and mortality including eclampsia, HELLP syndrome, acute renal failure, pulmonary edema, DIC, IUGR, IUFD, intracranial bleeding and stroke, Additionally, an earlier diagnosis could also impact patient care by reducing hospital stay, nursing demands, and eliminating the need for cumbersome and likely inaccurate patient 24-h home collections. ;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |